{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058812","form_type":"8-K","ticker":null,"cik":"0001764974","company_name":"Turnstone Biologics Corp.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.964104+00:00","generated_at":"2026-06-02T02:31:54.046930+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Turnstone Biologics Q1 2024 net loss $19.6M; cash $77.8M funds into Q3 2025","bullets":["Net loss of $19.6M vs $0.1M net income in Q1 2023, no collaboration revenue recognized.","Cash and short-term investments $77.8M as of March 31, 2024; expected to fund operations into Q3 2025.","R&D expenses $15.8M, flat YoY; G&A expenses $4.9M, up from $4.0M due to public company costs.","Secured $20M non-dilutive revolving credit facility from Banc of California in April 2024.","Appointed William Waddill to Board; Patrick Machado stepped down. TIDAL-01 Phase 1 update expected mid-year."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058812","json":"https://secwatch.observer/filing/0000950170-24-058812.json","markdown":"https://secwatch.observer/filing/0000950170-24-058812.md","text":"https://secwatch.observer/filing/0000950170-24-058812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764974/000095017024058812/0000950170-24-058812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764974/000095017024058812/tsbx-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:31:54.046930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00de8670c2653e10ae90e4ce7032fac46e4e5eb2","claim":"Turnstone Biologics Corp. reported first quarter ended March 31, 2024 results: net income Net loss was $19.6 million.","evidence_excerpt":"On May 13, 2024, Turnstone Biologics Corp. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764974/000095017024058812/0000950170-24-058812-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $19.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}